Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation.
about
Infections caused by Scedosporium spp.In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and CandidaAntifungal activities and cytotoxicity studies of six new azasordarinsSordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungiComparative analysis of pathogenic organisms in cockroaches from different community settings in Edo State, Nigeria.Rapid detection of Candida albicans in clinical samples by DNA amplification of common regions from C. albicans-secreted aspartic proteinase genes.Antifungal agents: chemotherapeutic targets and immunologic strategies.Pharmacokinetics and tissue penetration of fluconazole in rabbitsPhagocytosis of medically important yeasts by polymorphonuclear leukocytesComparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis.Molecular epidemiology of nosocomial invasive aspergillosis.Retrospective evaluation of two latex agglutination tests for detection of circulating antigens during invasive candidosis.Fungal infections in cancer patients.Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.Esophageal candidiasis. Managing an increasingly prevalent infection.Characterization of the Aspergillus nidulans aspnd1 gene demonstrates that the ASPND1 antigen, which it encodes, and several Aspergillus fumigatus immunodominant antigens belong to the same family.Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patientsAnalysis of Aspergillus nidulans conidial antigens and their prevalence in other Aspergillus species.Identification of clinical yeast isolates by using the Microring YT.Evaluation of the Baxter-MicroScan 4-hour enzyme-based yeast identification system.Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients.Empiric treatment of localized infections in the febrile neutropenic patient with monotherapy.Fungal ribotoxins: a family of naturally engineered targeted toxins?In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreusSubstituted 2-aminothiophenes: antifungal activities and effect on Microsporum gypseum protein profile.Systemic candidiasis: an unusual complication of eating mutton.Hepato-splenic mycotic abscesses in patients with acute leukemia.Potential use of liposomal diallyl sulfide in the treatment of experimental murine candidiasis.Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism.Evaluation of biochemical and serological methods to identify and clustering yeast cells of oral Candida species by CHROMagar test, SDS-PAGE and ELISA.Synthesis of Aryl Aldimines and Their Activity against Fungi of Clinical Interest
P2860
Q24657691-C7C4CFD1-3F00-4145-8758-CB4572EF616EQ28344464-1ABACBAE-D92C-4905-8DF0-A55E0E23D229Q28361573-8B12D8A2-167B-4305-B759-38A57911191FQ28369140-0D0FFA45-A2B6-4E77-8550-985B4BCAA0DEQ33639272-77BA2592-8DB4-4119-97E8-2B555159EF25Q33655898-8EA47323-8477-4846-8168-D91B66038F62Q34400044-DF120819-459D-470D-B9B5-03C6EE91A03AQ35325949-9B6BA50B-8DB8-490B-855D-EE390CE6F100Q35777368-21BBB176-96F1-4B94-97ED-9AC4222A4B8BQ36757381-626F2622-DE6E-4558-81C6-F973C7422453Q37073108-EA9C74CA-6285-49F1-853D-6C445157E5D9Q37125723-085E7D40-9DBD-4820-A3BE-44C41570CFE8Q37220788-4C5552C7-D167-4A42-AEB2-93086A5054DFQ38554220-06C28FD6-B25D-45FE-9EE2-763A78AFD2E1Q39473214-45DE871A-7E6C-432B-86AF-BC0FFC1656A0Q39511843-412794EF-9249-4518-B3F9-BBC50D9CA5EBQ39829452-015BA0AA-A2A5-4153-8F76-57D95AC95D60Q39865500-E4FD3F92-91A6-42FF-9AAB-F7FF05AF4E1EQ39866778-5956E2D5-B5F2-45CC-9937-4E4FD1DBBDC4Q40156243-61890C34-FEAB-4B14-96A9-702D48B1BC36Q40174083-94AFEA78-237B-4CF5-B894-F937899FFAD0Q40211619-37E723B0-CFCA-4017-A777-7DE33330C648Q40612999-4DAB7CA8-D64C-48B6-808D-88CFA87169A6Q40721491-6A1510F1-1703-4DA6-A48D-632867A00900Q41043840-068685E3-717D-4F6C-80BA-B275D3AE2EF0Q41788018-AD48D7FE-71E8-4697-B7C4-AD83D48DAB0FQ42727846-B36A443D-7265-4B74-8EB9-711A4BCCE939Q42878984-EE1E2D73-9131-4C1B-A826-9E0D54A0265EQ43462339-B0D5D40E-88D9-4A10-B2D5-355175E2713EQ45915910-A8B3FD6B-D3B8-4473-9B0D-BDEDA8F3B242Q51172068-F8A05F02-A38B-4E9C-BDB2-477599FEFDA3Q51605176-6C6C5E80-464F-41BC-9224-04587B362E7FQ58822364-00BB7C80-3AA7-4F11-B79F-8F7D2DCDEBAC
P2860
Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Nosocomial fungal infections: ...... ogenous flora or reactivation.
@en
Nosocomial fungal infections: ...... ogenous flora or reactivation.
@nl
type
label
Nosocomial fungal infections: ...... ogenous flora or reactivation.
@en
Nosocomial fungal infections: ...... ogenous flora or reactivation.
@nl
prefLabel
Nosocomial fungal infections: ...... ogenous flora or reactivation.
@en
Nosocomial fungal infections: ...... ogenous flora or reactivation.
@nl
P1476
Nosocomial fungal infections: ...... ogenous flora or reactivation.
@en
P2093
P304
P356
10.1146/ANNUREV.MI.42.100188.002505
P577
1988-01-01T00:00:00Z